✦ LIBER ✦

Overcoming Resistance Against HER2-Targeting Agents in Fifth-Line Therapy: Is There Still a Place for Bevacizumab in HER2+ Breast Cancer?

✍ Scribed by Huemer, Florian; Gampenrieder, Simon Peter; Schlattau, Alexander; Greil, Richard

Book ID: 123326524
Publisher: CIG Media Group, LP.
Year: 2014
Tongue: English
Weight: 498 KB
Volume: 14
Category: Article
ISSN: 1526-8209
DOI: 10.1016/j.clbc.2013.09.009

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Is there a case for anti-HER2 therapy wi

Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?

✍ Anastasia Constantinidou; Ian Smith 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 113 KB

A novel inhibitor of fatty acid synthase

A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines

✍ Teresa Puig; Helena Aguilar; Sílvia Cufí; Glòria Oliveras; Carlos Turrado; Sílvi 📂 Article 📅 2011 🏛 BioMed Central 🌐 English ⚖ 676 KB

AVEREL: A Randomized Phase III Trial Eva

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

✍ Gianni, Luca (author);Romieu, Gilles H. (author);Lichinitser, Michail (author);S 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 205 KB

AVEREL: A Randomized Phase III Trial Eva

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

✍ Gianni, Luca (author);Romieu, Gilles H. (author);Lichinitser, Michail (author);S 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 205 KB